October 2026 Global Biopharma Deal Roundup: Billion-Dollar Licensing, Strategic Acquisitions and Platform Partnerships

In October 2026, global biopharma dealmaking was characterized by a combination of high-value licensing agreements, platform collaborations and strategic acquisitions. In oncology, antibody-drug conjugates (ADCs), T-cell engagers (TCEs) and emerging immunotherapies continued to attract investment from major pharmaceutical companies. In autoimmune and inflammatory diseases, partnerships spanned B-cell depletion, claudin-targeted therapies, oral peptides and multispecific antibodies. Emerging approaches, including RNA therapeutics, AI-driven protein drug design, brain-delivered enzyme replacement therapies and Sec61-mediated protein homeostasis modulation, also secured commercial support. Deal structures ranged from single-asset licenses to multi-program options, platform agreements, acquisitions and reverse mergers, highlighting the industry’s pursuit of both near-term pipeline expansion and scalable innovation platforms.

• October 10 | ClearideBio Therapeutics AG and MicuRx-MRX-23 ADC and Up to Six STOPIN Platform Options; Potential Value Up to $973 Million

Shanghai MicuRx Pharmaceutical Co., Ltd. (MicuRx) announced plans to enter into two agreements with ClearideBio Therapeutics AG: an exclusive worldwide license for the preclinical ADC MRX-23 and an option-based collaboration covering up to six targets or target combinations using MicuRx’s STOPIN ADC platform. MicuRx will retain the platform’s core intellectual property. The molecular target and intended indications of MRX-23 have not been disclosed.

• October 14 | Gilead Sciences and Vir Biotechnology-Three PRO-XTEN Dual-Masked TCEs; Potential Value Up to $1.875 Billion

The partners will discover and engineer three dual-masked T-cell engager candidates directed against solid tumor-associated antigens. Vir Biotechnology will lead candidate discovery and protein engineering, while Gilead will hold exclusive worldwide rights to develop and commercialize the resulting candidates. PRO-XTEN masking technology is designed to enable TCE activation preferentially within the tumor microenvironment, potentially reducing unintended T-cell activation in healthy tissues.

• October 19 | Roche and Hansoh Pharma-Multi-Program ADC Portfolio and Technology Platform Collaboration; Potential Value $15.51+Billion

The agreement covers two preclinical ADC programs from Hansoh Pharma and additional programs based on Roche-selected targets and Hansoh’s ADC technology platform. Hansoh will lead early development through completion of global Phase 1a trials, after which Roche will assume further development outside mainland China, Hong Kong, Macao and Taiwan. Hansoh retains development and commercialization rights in those territories.

• October 22 | The Menarini Group/Stemline Therapeutics and Georgiamune-GIM-621 Oral Immuno-Oncology Candidate; Potential Value Up to $1.1 Billion

Stemline Therapeutics, a subsidiary of the Menarini Group, secured exclusive worldwide development, manufacturing and commercialization rights to GIM-621, a preclinical candidate. Positioned as a potential first-in-class oral small-molecule immunotherapy, GIM-621 is being explored for multiple solid tumors. Its specific molecular targets, mechanism of action and initial indications have not been publicly disclosed.

• October 23 | Roche and Zymeworks-ZW209 (DLL3/CD3/CD28 Trispecific TCE); Potential Value Up to $813 Million

Roche obtained exclusive worldwide rights to develop and commercialize ZW209. The trispecific TCE is designed to engage DLL3 on tumor cells and CD3 and CD28 on T cells, with a focus on small-cell lung cancer and other DLL3-expressing neuroendocrine tumors. Zymeworks will participate in the Phase 1a study; Roche will lead subsequent global development and commercialization.

• October 28 | Astellas Pharma and Audax Biosciences-DAX-044 (IL-12 Antibody–Cytokine Fusion); Potential Value Up to $1.335 Billion

Astellas obtained an exclusive option for a worldwide license to develop and commercialize DAX-044. Based on Audax’s AVIKINE technology, this antibody–cytokine fusion is designed to concentrate IL-12-mediated immune activation within the tumor microenvironment while limiting systemic toxicity. The candidate is currently undergoing IND/CTN-enabling studies, with a Phase 1 trial expected to begin in 2027. If Astellas exercises its option, it will assume responsibility for subsequent global development, manufacturing and commercialization.

• October 1 | Sanofi and Regeneron-Long-Acting IL-13, IL-4 xIL-13 and Other Immunology Antibodies; Potential Value Up to $8 Billion

Sanofi and Regeneron expanded their longstanding antibody alliance to include the clinical-stage long-acting IL-13 monoclonal antibody REGN20423, a long-acting IL-4 x IL-13 bispecific antibody and two additional preclinical long-acting antibodies. Regeneron will lead research and development, while Sanofi will lead global commercial activities.

• October 2 | Novartis and Abogen Biosciences-ABO2203 (mRNA-Encoded CD19 xCD3 TCE) and Other RNA Programs; Potential Value Up to $7.775 Billion

Novartis secured an exclusive worldwide license to ABO2203 and exclusive options to license other RNA programs from Abogen Biosciences. ABO2203 uses mRNA to direct the in vivo expression of a CD19 x CD3 T-cell engager, with the aim of depleting B cells in B-cell-mediated autoimmune diseases.

• October 5 | CSL and Alentis Therapeutics-Lixudebart (Anti-CLDN1 Monoclonal Antibody); Potential Value Up to $1.555 Billion

CSL and Alentis Therapeutics entered into a global collaboration to co-develop and commercialize lixudebart, an anti-claudin-1 (CLDN1) monoclonal antibody. The ongoing Phase 2 RENAL trial is evaluating the candidate in ANCA-associated vasculitis with rapidly progressive glomerulonephritis. Further development is planned in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC).

• October 22 | Gilead Sciences and PepStar Therapeutics-HCXT-2001 (Oral IL-23R Macrocyclic Peptide Inhibitor); $1.275 Billion Cash Acquisition

Gilead agreed to acquire PepStar Therapeutics’ oral IL-23R inhibitor program, including the lead candidate HCXT-2001, for $1.275 billion in cash. HCXT-2001 is a clinical-stage, long-acting oral macrocyclic peptide currently in Phase 1 development for immune-mediated inflammatory conditions, including inflammatory bowel disease. The acquisition extends therapeutic targeting of the clinically validated IL-23 pathway into an oral peptide modality.

• October 23 | Bolt Biotherapeutics and Prana Therapies-PRA-216 (IL-4Rα/TSLP Bispecific Antibody); $120 Million Private Placement Plus Up to $60 Million from Warrants

Bolt Biotherapeutics acquired Prana Therapies through a reverse merger, gaining its INSPIRE platform for half-life-extended multispecific antibodies. The lead candidate, PRA-216, targets IL-4Rα and TSLP and is being studied in Phase 2 trials in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 trial planned in eosinophilic esophagitis.

• October 13 | Roche and Rona Therapeutics-ALK7 (ACVR1C)-Targeted RNAi; Potential Value Up to $1.16 Billion

Roche obtained an exclusive worldwide license to Rona Therapeutics’ investigational RNAi candidate targeting ALK7, which is encoded by ACVR1C. ALK7 is predominantly expressed in adipose tissue. Using an extrahepatic delivery strategy, the program aims to modulate visceral and ectopic fat deposition through direct targeting of adipocytes, with potential applications in obesity and other metabolic diseases.

• October 13 | Zealand Pharma and Generate Biomedicines-AI-Engineered Multispecific Proteins (Targets Undisclosed); Potential Value $1.2+Billion

The companies will combine Zealand Pharma’s expertise in metabolic diseases with Generate Biomedicines’ generative AI platform to develop multispecific protein therapeutics for obesity and other metabolic conditions. The initial collaboration covers two programs, with an option to add a third. Specific targets have not been disclosed.

• October 15 | AstraZeneca and insitro-AI-Driven Target Discovery for MASH and Cardiomyopathies; Potential Value Up to $1.5 Billion

The parties established an exclusive worldwide research collaboration using insitro’s Virtual Human causal AI platform to identify new therapeutic targets and advance drug discovery in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. AstraZeneca will hold exclusive worldwide development rights to selected programs.

• October 5 | Genentech (Roche Group) and Alector-AL050 (Brain-Penetrant GCase Enzyme Replacement Therapy); Potential Value Up to $1.27 Billion

Genentech secured exclusive worldwide rights to develop and commercialize AL050, Alector’s investigational brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. The program uses Alector Brain Carrier, a blood–brain barrier delivery platform, and is intended for Parkinson’s disease and other neurodegenerative conditions.

• October 8 | Viatris and Pacira BioSciences-EXPAREL and ZILRETTA Non-Opioid Pain Portfolio; $1.65 Billion Cash Acquisition

Pacira BioSciences markets EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain and ZILRETTA (extended-release triamcinolone acetonide) for pain associated with knee osteoarthritis. The proposed acquisition is primarily focused on integrating established commercial products, intellectual property and market capabilities rather than acquiring an early-stage pipeline asset.

• October 5 | Shionogi and IntraBio-AQNEURSA (Levacetylleucine) and Rare Neurological Disease Pipeline; $2 Billion Cash Acquisition

AQNEURSA has been approved for the treatment of neurological manifestations of Niemann–Pick disease type C. In September 2026, the U.S. FDA also approved it for the treatment of ataxia in patients with ataxia-telangiectasia.

October 19 | Merck KGaA, Darmstadt, Germany, and Silence Therapeutics | Divesiran (TMPRSS6 siRNA) and RNAi Platform; Approximately $1.3 Billion Equity Value

Merck KGaA, Darmstadt, Germany, agreed to acquire Silence Therapeutics in an all-cash transaction. The lead asset, divesiran, is an siRNA therapy targeting TMPRSS6 and modulating iron metabolism through hepcidin regulation. It is being developed for polycythemia vera, having completed Phase 2 evaluation and progressed into preparations for Phase 3 development.

• October 20 | Alcon and Neurotech Pharmaceuticals-ENCELTO (Encapsulated Cell/CNTF Therapy); $550 Million Acquisition

Alcon announced its acquisition of Neurotech Pharmaceuticals and its commercial-stage asset ENCELTO. The product involves the intraocular implantation of encapsulated, engineered allogeneic retinal pigment epithelial cells that continuously release recombinant human ciliary neurotrophic factor (rhCNTF). ENCELTO treats adults with idiopathic macular telangiectasia type 2 (MacTel type 2); approved by the U.S. FDA in March 2025, it is the first and currently only FDA-approved treatment for this indication.

• October 29 | BioMarin, GC Biopharma and Hanmi Pharm-HM15421/GC1134A (Alpha-Galactosidase A Enzyme Replacement Therapy); Potential Value Up to $475 Million

BioMarin obtained exclusive development and commercialization rights to HM15421/GC1134A worldwide, excluding South Korea. The investigational long-acting recombinant alpha-galactosidase A enzyme replacement therapy is administered subcutaneously and is being evaluated in a Phase 1/2 trial in patients with Fabry disease. It has the potential to become the first subcutaneous enzyme replacement treatment for this disease.

• October 5 | Eli Lilly and Gate Bioscience-Molecular Gate (Sec61-Related Small-Molecule Protein Degradation); Potential Value Exceeding $870 Million

Eli Lilly expanded its 2025 collaboration with Gate Bioscience to include an additional research target and an option for a second. Gate uses its Molecular Gate platform to design orally administered small molecules that selectively prevent target proteins from entering the secretory pathway through the Sec61 translocon, thereby promoting their degradation. The specific targets and indications remain undisclosed.

• October 13 | Pfizer and Enodia Therapeutics-Sec61-Targeting Small Molecules and Nascent Protein Degradation Platform; Potential Value $500+Million

Pfizer and Enodia Therapeutics entered into a research collaboration and license agreement to discover and develop Sec61 inhibitors against multiple undisclosed targets. Enodia’s platform selectively modulates the Sec61 translocon to suppress the production of particular disease-associated proteins during synthesis and translocation, while aiming to preserve essential physiological functions. Enodia will oversee early discovery, optimization and candidate development; Pfizer will lead subsequent clinical development, manufacturing, regulatory activities and commercialization.

Three themes stood out in October’s dealmaking. First, ADCs and TCEs remained central to oncology partnerships, with companies moving beyond individual asset licenses toward multi-program and technology-platform deals. Second, autoimmune and inflammatory disease strategies became more diverse, spanning RNA-encoded therapeutics, oral macrocyclic peptides, bispecific antibodies and emerging membrane protein targets. Third, early-stage platforms in AI-enabled protein design, tissue-targeted RNAi, brain delivery and Sec61-mediated protein homeostasis began to enter large-pharma pipelines through cross-company partnerships.